Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.

The prognostic impact of complex karyotype in CLL is nuanced and not a simple high-risk flag. It's most significant with five or more abnormalities combined with other factors like a P53 mutation. Specific subtypes, such as those with trisomy 12 and 19, may not confer a poor prognosis.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

A key clinical nuance in CLL is that not all prognostic markers are static. The IGHV mutation status remains unchanged, requiring a one-time test. However, chromosomal abnormalities like deletion 17p can evolve, necessitating re-evaluation at each relapse to guide subsequent therapy choices and adapt the treatment strategy.

The FLAIR trial's MRD-guided protocol, while effective, created a paradox. Lower-risk, IGHV-mutated patients, who typically do well on shorter treatments, took longer to achieve undetectable MRD. This resulted in them receiving a longer duration of therapy than their higher-risk counterparts, representing likely overtreatment.

Current CAR-T therapy for CLL requires a complete response (CR) for long-term benefit. A partial response provides only about two years of disease control, an outcome similar to the oral drug pirtobrutinib but with significantly more toxicity, complexity, and logistical burden for the patient.

Recent non-inferiority trials affirm that fixed-duration combination therapies are viable alternatives to continuous BTK inhibitors. However, clinicians must look beyond the headline conclusion, as numerical data can show slightly worse progression-free survival for high-risk subgroups within the acceptable non-inferiority margin, complicating treatment decisions.